Droperidol

CHEMBL1108 Phase 4 Đã phê duyệt Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

379.4 g/mol

LogP

3.5

Phase

4

A butyrophenone antipsychotic and antiemetic used to prevent nausea and vomiting during surgery and anesthesia, and to treat acute agitation. It blocks dopamine receptors in the brain.

Khối lượng phân tử

379,4000 g/mol

LogP

3,50

TPSA

52,70 Å²

Lipinski RO5

Đạt

Lĩnh vực điều trị

Pain Management Non-Small Cell Lung Cancer Migraine Schizophrenia Obesity Breast Cancer Chronic Pain

Cơ chế tác dụng

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Cấu trúc 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1

InChI

InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)

Molecular Formula

C22H22FN3O2

HBD / HBA

1 / 4

Liên kết có thể quay

6

Nguyên tử nặng

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A butyrophenone antipsychotic and antiemetic used to prevent nausea and vomiting during surgery and anesthesia, and to treat acute agitation. It blocks dopamine receptors in the brain.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Droperidol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1108. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3168. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Bạn đang tìm kiếm thông tin thân thiện với bệnh nhân?

Droperidol trên PillFYI

Cấu trúc

Dữ liệu nhanh

Công thức: C22H22FN3O2
Tên đồng nghĩa: 1

Liên kết ngoài

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.